| 11.16 -0.01 (-0.09%) | 12-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.53 |
1-year : | 15.81 |
| Resists | First : | 11.59 |
Second : | 13.53 |
| Pivot price | 10.41 |
|||
| Supports | First : | 10.43 |
Second : | 9.72 |
| MAs | MA(5) : | 10.73 |
MA(20) : | 10.43 |
| MA(100) : | 9.02 |
MA(250) : | 0 | |
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 69.2 |
D(3) : | 59.2 |
| RSI | RSI(14): 61.3  |
|||
| 52-week | High : | 16.66 | Low : | 4.32 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PRTA ] has closed Bollinger Bands are 9.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.6 - 11.66 | 11.66 - 11.72 |
| Low: | 10.81 - 10.88 | 10.88 - 10.93 |
| Close: | 11.05 - 11.16 | 11.16 - 11.26 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Thu, 04 Dec 2025
Prothena (NASDAQ:PRTA) Stock Price Up 7.4% - Here's Why - MarketBeat
Tue, 02 Dec 2025
Citizens Jmp Forecasts Strong Price Appreciation for Prothena (NASDAQ:PRTA) Stock - MarketBeat
Mon, 01 Dec 2025
Citizens Raises Price Target for Prothena Corp (PRTA) to $19.00 - GuruFocus
Sun, 30 Nov 2025
Why (PRTA) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Thu, 30 Oct 2025
Prothena to Report Third Quarter 2025 Financial Results on November 6 - Business Wire
Wed, 22 Oct 2025
Prothena Corporation plc (PRTA): A Bull Case Theory - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 4.339e+007 (%) |
| Held by Institutions | 19.2 (%) |
| Shares Short | 3,860 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.2135e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 646.4 % |
| Return on Equity (ttm) | -29.4 % |
| Qtrly Rev. Growth | 1.179e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -188 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.23 |
| Dividend | 0 |
| Forward Dividend | 4.66e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|